Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

Better knowledge of the tumor genomic landscapes has helped to develop more effective targeted drugs. However, there is no tool to interpret targetability of genomic alterations assessed by next-generation sequencing in the context of clinical practice. Our aim is to rank the level of evidence of in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2019-03, Vol.30 (3), p.365-373
Hauptverfasser:	Condorelli, R., Mosele, F., Verret, B., Bachelot, T., Bedard, P.L., Cortes, J., Hyman, D.M., Juric, D., Krop, I., Bieche, I., Saura, C., Sotiriou, C., Cardoso, F., Loibl, S., Andre, F., Turner, N.C.
Format:	Artikel
Sprache:	eng
Schlagworte:	BRCA1 Protein - genetics BRCA2 Protein - genetics breast cancer Breast Neoplasms - genetics Breast Neoplasms - pathology Breast Neoplasms - therapy Class I Phosphatidylinositol 3-Kinases - genetics Female Genome, Human - genetics genomic alterations Genomic Instability - genetics Humans Molecular Targeted Therapy Mutation - genetics Neoplasm Staging precision medicine Proto-Oncogene Proteins c-akt - genetics Proto-Oncogene Proteins c-mdm2 - genetics Receptor, ErbB-2 - genetics target prioritization targeted therapies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!